Clinical trials: Human Immunodeficiency Virus Type 1
Maternal-fetal Infection Transmission
Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors
The overall goal is to study the feasibility of darunavir/ritonavir (DRV/r) monotherapy as treatment simplification (switch) in pretreated pregnant women, associated with neonatal prophylaxis with nevirapine, constituting a PMTCT…
- Trial name
- MONOGEST (NCT02738502)
- Testing
- darunavir monotherapy
- Where
- 23 sites in France
- Volunteers
- 91 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infections
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
This post-marketing observational study is conducted for obtaining data on clinical, biological and virological outcomes, compliance and tolerability of using a lopinavir/ritonavir (LPV/r) -containing regimen for the treatment of…
- Trial name
- NCT01074931
- Testing
- Lopinavir/ritonavir (Kaletra)
- Where
- 5 sites in China
- Volunteers
- 98 people
- Sponsor
- Abbott
HIV-1 Infection
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
The primary objectives of this study are: Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day…
- Trial name
- NCT03739866
- Testing
- Lenacapavir, B/F/TAF, TAF
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Gilead Sciences
HIV Infections
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
This multicenter, retrospective, observational study will evaluate the therapeutic effectiveness of a strategy of induction with Fuzeon (enfuvirtide) within an optimized regimen of antiretroviral drugs in patients with HIV-1…
- Trial name
- NCT01902615
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
HIV Seropositivity
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia
Prospective, open-label, single arm, non-randomized, proof-of-concept study. Eligible patients will sign a written informed consent and will be followed-up at screening, baseline (ART interruption) and at 1, 2, 3, 4, 6, 8, 10…
- Trial name
- APACHE (NCT03198325)
- Testing
- Stop of ART
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- IRCCS San Raffaele
HIV
Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin)…
- Trial name
- NCT02616874
- Testing
- MVA.HIVconsv vaccine, Romidepsin
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- IrsiCaixa
HIV Infections
Dasatinib for HIV-1 Reservoir Reduction
This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed…
- Trial name
- NCT07342491
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART
To determine the short-term virologic and immunologic effects of using plasma genotypic antiretroviral resistance testing (GART) results (interpreted by study virologists AS PER AMENDMENT 9/17/97) in the management of therapy for…
- Trial name
- NCT00000874
- Where
- 24 sites in United States
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of…
- Trial name
- NCT02881320
- Testing
- B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
- Where
- 25 sites in United States, South Africa and 2 more
- Volunteers
- 177 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-controlled 'proof of concept' study is to be…
- Trial name
- NCT00708110
- Testing
- GSK1349572
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- ViiV Healthcare
HIV Infections
Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
The purpose of this study is to compare the proportion of subjects with HIV-1 RNA viral load < 50 c/mL through Week 48 of the Maintenance Phase among HIV-infected subjects with an initial undetectable viral load following an…
- Trial name
- INDUMA (NCT00207142)
- Testing
- Atazanavir + 2 NRTIs, Atazanavir + Ritonavir + 2 NRTIs
- Where
- 27 sites in Estonia, France and 8 more
- Volunteers
- 252 people
- Sponsor
- Bristol-Myers Squibb
Neuropathy
Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy
The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.
- Trial name
- NCT01049217
- Testing
- pregabalin
- Where
- 63 sites in United States, Colombia and 7 more
- Volunteers
- 377 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
HIV Infections
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
The purpose of this study was to assess the safety, tolerability, antiviral activity, and pharmacokinetics of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody VRC-HIVMAB075-00-AB (VRC07-523LS)…
- Trial name
- NCT03739996
- Testing
- Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Human Immunodeficiency Virus
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.
- Trial name
- NCT02175680
- Testing
- PRO 140, Historical data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- CytoDyn, Inc.
Infection, Human Immunodeficiency Virus
Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients
This study is a cross sectional observational study to evaluate the prevalence of HLA-B*5701 in the major French ethnotypes. Any HIV-1 infected subject will be eligible for this study including antiretroviral therapy (ART) naÃ-ve…
- Trial name
- NCT00441688
- Testing
- GI265235
- Volunteers
- 974 people
- Sponsor
- ViiV Healthcare
HIV Infection
Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
To date, all work related to the study of HIV tropism, was performed on HIV B and C subtypes. In the studied samples, HIV variants of subtype A were virtually absent.
- Trial name
- CoTrAST (NCT01823614)
- Where
- Russia
- Volunteers
- 943 people
- Sponsor
- Dmitry Kireev
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV
Exploratory Study on the Role of the Digestive Microbiota in Adults Living With HIV-1
Chronic immune activation present in aviremic people living with HIV under treatment promotes the onset of insulin resistance and metabolic syndrome, paving the way for the comorbidities that are currently the main causes of…
- Trial name
- MICRACTIVIH (NCT05724524)
- Testing
- Stool sample collection, Blood sample collection
- Where
- 2 sites in France
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
HIV-1 Infection
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of…
- Trial name
- NCT02652624
- Testing
- E/C/F/TAF, E/C/F/TDF, ATV
- Where
- 56 sites in United States, Dominican Republic and 4 more
- Volunteers
- 472 people
- Sponsor
- Gilead Sciences
HIV-1, HIV Infections
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
The goal of this study is to understand the safety, tolerability and immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd 5 HIV-1 gag/pol/nef) vaccine in healthy human volunteers compared…
- Trial name
- NCT00849680
- Testing
- Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.